- Syneos Health was formed in 2017 via a merger between 2 Contract Research Organizations, INC Research and inVentiv Health.
- From a share price perspective progress was slow initially, before the stock price gained 98% between late 2020 - late 2021.
- CROs operate in an attractive market - running clinical trials on behalf of biotech and pharma clients - and Syneos is profitable and growing.
- After a rocky start to 2022, Syneos' share price has fallen ~20% to $79 - I suspect this correction - which has affected the entire sector - is temporary.
- Syneos may also be an M&A target - perhaps for Charles River, or more likely, LabCorp. Overall, Syneos stock looks undervalued when we consider the opportunities and the downside risk mitigation.
For further details see:
Syneos Health: Upside Opportunity After Unexpected Correction In CRO Market, M&A Rumors